Skip to main content
H

HANS BIOMED CORPORATION — Investor Relations & Filings

Ticker · 042520 ISIN · KR7042520007 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2024-09-13 Notice of Dividend Amou…
Country KR South Korea
Listing KO 042520

About HANS BIOMED CORPORATION

http://www.hansbiomed.com/en/

HANS BIOMED CORPORATION is a biotechnology company that develops, manufactures, and sells high-tech medical materials, devices, and biologics. The company's core focus is on regenerative medicine and tissue engineering. Its product portfolio includes silicone breast implants, allograft tissue products for skin and bone grafts, and absorbable lifting sutures for aesthetic procedures. The company also offers professional cosmeceutical products. HANS BIOMED supports its operations through a dedicated tissue engineering research laboratory and a human tissue bank, aiming to provide innovative solutions for the global medical and aesthetic markets.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the procedural steps for the meeting. Given the nature of the announcement as a regulatory disclosure of corporate action, it fits best under the RNS category.
2024-09-13 Korean
분기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for HansBiomed Corp, covering the period from October 1, 2023, to June 30, 2024. It contains detailed financial data, business operations, management discussions, and capital structure information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-08-14 Korean
반기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for HansBiomed Corp, covering the period from October 1, 2023, to March 31, 2024. It contains detailed financial data, business operations, management information, and capital structure, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details changes to previously granted stock options, including the number of shares and the list of recipients. This type of filing relates to capital structure and equity compensation, which falls under the 'Regulatory Filings' category as it is a specific corporate disclosure required by financial authorities (Financial Services Commission/Korea Exchange) that does not fit into the other specialized categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2024-04-01 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event, specifically a Non-Deal Roadshow (NDR). It provides details such as the date, location, purpose, and contact information for the event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2024-03-27 Korean
[기재정정]분기보고서 (2023.12)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for HansBiomed Corp, covering the period from 2023-10-01 to 2023-12-31. It contains detailed financial statements, management discussion, and operational data. It is a formal regulatory filing submitted to the Financial Supervisory Service (FSS) in Korea. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2023
2024-02-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.